Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of MRG002 plus HX008 in HER2-expressing advanced malignant solid tumors
CTR20220485Phase 2Completed
- Sponsor
- Hangzhou Miracogen
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MRG002, pucotenlimab in Nonhematologic neoplasms, sponsored by Hangzhou Miracogen. Started Aug 2022; status: completed.
02
Drugs
MRG002pucotenlimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20220485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220485.